Z-VDVAD-FMK

Z-VDVAD-FMK

• CAS Number: 210344-92-6
• UNSPSC Description: Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis[1][2][3].
• Target Antigen: Caspase
• Type: Peptides
• Related Pathways: Apoptosis
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/z-vdvad-fmk.html
• Purity: 98.0
• Solubility: DMSO : 250 mg/mL (ultrasonic)
• Smiles: O=C(N[C@@H](C(C)C)C(N[C@@H](CC(OC)=O)C(N[C@H](C(N[C@@H](C)C(N[C@H](C(CF)=O)CC(OC)=O)=O)=O)C(C)C)=O)=O)OCC1=CC=CC=C1
• Molecular Weight: 695.73
• References & Citations: [1]S Gamen, et al. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 2000 Jul 10;258(1):223-35. |[2]Cédric Sapet, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood. 2006 Sep 15;108(6):1868-76. |[3]Simon W Rabkin, et al. Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicol Appl Pharmacol. 2003 Dec 15;193(3):346-55.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported